AbbVie
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
ABBV Key Statistics
Stock Snapshot
As of today, AbbVie(ABBV) shares are valued at $228.25. The company's market cap stands at 406.29B, with a P/E ratio of 171.97 and a dividend yield of 2.9%.
On 2025-12-24, AbbVie(ABBV) stock moved within a range of $227.91 to $230.79. With shares now at $228.25, the stock is trading +0.1% above its intraday low and -1.1% below the session's peak.
Trading volume for AbbVie(ABBV) stock has reached 3.38M, versus its average volume of 6.82M.
Over the past 52 weeks, AbbVie(ABBV) stock has traded between a high of $244.81 and a low of $164.39.
Over the past 52 weeks, AbbVie(ABBV) stock has traded between a high of $244.81 and a low of $164.39.
ABBV News
Abbvie (ABBV) announced an update on their ongoing clinical study. Claim 70% Off TipRanks This Holiday Season Unlock hedge-fund level data and powerful investin...
In one sense, there's no such thing as easy money. However, once you have money accumulated to invest, it can be easy to make more. That's the key to generating...
In December 2025, OSE Immunotherapeutics announced it had amended its partnership with AbbVie on pre-clinical anti-inflammatory antibody ABBV-230, taking back r...
Analyst ratings
70%
of 30 ratingsMore ABBV News
Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model ba...
Key Points AbbVie is a pharmaceutical company with a focus on immunology, oncology, neuroscience, and aesthetics. The company's third-quarter earnings were do...
Key Points Invest in stocks with good fundamentals, solid growth prospects, and steady dividends. These blue chip stocks have strong businesses that generate...
Investors in AbbVie Inc (Symbol: ABBV) saw new options become available today, for the August 2026 expiration. One of the key inputs that goes into the price an...
AbbVie Inc. (NYSE:ABBV) and several other drugmakers are reportedly expected to announce agreements with the U.S. government on Friday to cut select prescriptio...
AbbVie (ABBV) stock was down slightly on Thursday after reports claimed that the company was set to meet with President Donald Trump to negotiate agreements for...
...
